Loading...
Loading...
HAIFA, Israel, Jan. 7, 2013 (GLOBE NEWSWIRE) --
Dear Pluristem Shareholders,
In 2012 we have made great progress and moved closer to fulfilling our vision of being a leader in developing and manufacturing cell therapies. We have had significant achievements in many areas including:
Clinical trials development activity
Exploring new potential product candidates
Enhancing our IP position
Insured financial soundness and joining the Tel Aviv 75 and 100 indexes
Constructing a new state of the art manufacturing facility for our PLX Cells
Clinical trials development activity
Achievements in clinically developing our products attest to the hard work, dedication and ingenuity that our team demonstrates on a daily basis. In 2012 our milestones included:
The initiation of an FDA-approved Phase II clinical trial using PLX cells for the treatment of Intermittent Claudication (IC), a form of Peripheral Artery Disease (PAD)
The approval by the Paul Erhlich Institute (PEI), the German medical regulatory body, to commence a Phase I/II clinical trial for the rehabilitation of injured gluteal muscles following a total hip replacement
The filing with the FDA for Orphan Drug Status in using our PLX cells in the treatment of Aplastic Anemia (a disease involving bone marrow failure)
The successful treatment of critically ill patients under a compassionate use program at the Hadassah Medical
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in